Synapse Open Synapse
Biology

Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC

Nature Biological Sciences · · 1 min read

Nature Reviews Clinical Oncology - Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC

Latest from Nature Biological Sciences